Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma × 1-dodecylpyridoxal × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3 Breast Neoplasms 3 Multiple Myeloma 2 Stomach Neoplasms 1 Sarcoma 1 Platinum-resistant Recurrent Ovarian Cancer 1 Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1 Lymphoma, Follicular 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 214 Rituximab 198 Etoposide 124 Filgrastim 101 Vincristine 98 Doxorubicin 91 Cytarabine 82 Prednisone 77 Radiotherapy 73 Methotrexate 70 Melphalan 65 fludarabine phosphate 64 Peripheral Blood Stem Cell Transplantation 64 Busulfan 52 Dexamethasone 45 Carmustine 42 Tacrolimus 39 Mycophenolic Acid 38 fludarabine 37 Granulocyte Colony-Stimulating Factor 37 Ifosfamide 35 Antilymphocyte Serum 35 Whole-Body Irradiation 31 sargramostim 29 Gemcitabine 28 Bortezomib 28 Cyclosporine 27 Methylprednisolone 25 Bendamustine Hydrochloride 25 Cisplatin 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06425302 2026-01-08

GOLSEEK-2

Celgene

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡